Bruker Corporation (BRKR) To Go Ex-Dividend on June 22nd

Bruker Corporation (NASDAQ:BRKR) declared a quarterly dividend on Thursday, May 14th. Investors of record on Monday, June 22nd will be paid a dividend of 0.05 per share by the medical research company on Tuesday, July 7th. This represents a c) annualized dividend and a yield of 0.3%. The ex-dividend date is Monday, June 22nd.

Bruker has increased its dividend payment by an average of 0.0%per year over the last three years. Bruker has a payout ratio of 7.3% meaning its dividend is sufficiently covered by earnings. Research analysts expect Bruker to earn $2.44 per share next year, which means the company should continue to be able to cover its $0.20 annual dividend with an expected future payout ratio of 8.2%.

Bruker Price Performance

Shares of NASDAQ BRKR opened at $57.23 on Friday. The firm has a market capitalization of $8.71 billion, a P/E ratio of -238.46, a P/E/G ratio of 1.83 and a beta of 1.31. The firm’s 50-day moving average price is $46.54 and its 200-day moving average price is $44.14. The company has a current ratio of 1.55, a quick ratio of 0.72 and a debt-to-equity ratio of 0.67. Bruker has a 1-year low of $28.53 and a 1-year high of $64.54.

Bruker (NASDAQ:BRKR) last issued its earnings results on Wednesday, May 6th. The medical research company reported $0.31 EPS for the quarter, beating the consensus estimate of $0.23 by $0.08. The company had revenue of $823.40 million during the quarter, compared to the consensus estimate of $795.62 million. Bruker had a positive return on equity of 11.60% and a negative net margin of 0.65%.During the same period last year, the business posted $0.47 EPS. The firm’s revenue for the quarter was up 2.7% compared to the same quarter last year. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Equities research analysts anticipate that Bruker will post 2.12 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, VP Mark Munch sold 2,000 shares of the stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $39.90, for a total value of $79,800.00. Following the completion of the sale, the vice president directly owned 128,443 shares of the company’s stock, valued at approximately $5,124,875.70. This represents a 1.53% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 27.20% of the company’s stock.

Institutional Trading of Bruker

Several institutional investors have recently made changes to their positions in the company. Royal Bank of Canada lifted its position in shares of Bruker by 8.3% during the first quarter. Royal Bank of Canada now owns 123,336 shares of the medical research company’s stock valued at $5,148,000 after purchasing an additional 9,501 shares in the last quarter. Jacobs Levy Equity Management Inc. bought a new stake in Bruker in the 1st quarter worth about $262,000. Goldman Sachs Group Inc. increased its stake in Bruker by 107.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,465,319 shares of the medical research company’s stock valued at $61,162,000 after buying an additional 758,301 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Bruker by 2.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 366,204 shares of the medical research company’s stock worth $15,285,000 after buying an additional 9,235 shares in the last quarter. Finally, Focus Partners Wealth lifted its position in shares of Bruker by 115.0% during the 1st quarter. Focus Partners Wealth now owns 11,232 shares of the medical research company’s stock worth $469,000 after buying an additional 6,008 shares in the last quarter. Institutional investors own 79.52% of the company’s stock.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.